The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

NCT05317767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

OTHER_GOV

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Flu-M [Inactivated split influenza vaccine]
BIOLOGICAL: Inactivated Split Influenza Vaccine

Sponsor

St. Petersburg Research Institute of Vaccines and Sera